Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)
NCT ID: NCT04443712
Last Updated: 2020-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1900 participants
OBSERVATIONAL
2020-05-29
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ain Shams University Experience: Clinical Determinants of Hospitalized COVID-19 Patients
NCT04584606
Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04853901
Evaluation of The Efficacy of Triazavirin Versus Oseltamivir in Egyptian Patients Infected With COVID-19
NCT04973462
Survival and 30-days Hospital Outcome in COVID-19 Patients in Upper Egypt
NCT04488588
Plasma Rich Antibodies From Recovered Patients From COVID19
NCT04348877
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study population: All patients needing admission in Ain-Shams University Hospitals are eligible for the study.
Sample size: There is no incidence data published till now. Only the confirmed detected cases have been reported. We assumed that the community cases are around 10 times that of detected cases.
it was estimated to be 1900 patients with 95% confidence level given the frequency of positive screening 0.05% with precision ± 0.1%. 10
The patients will be enrolled in the study using consecutive sample till the sample size is achieved.
Study methods:
Every enrolled patient will be subjected to:
1. An interview questionnaire including personal data ( age, gender, residence , contact details ) , epidemiological data (history of contact to a COVID-19 case, History of travel), clinical data history ( Fever, Cough, sore throat)
2. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
3. Antibody IgM-IgG test for SARS-CoV-2
Statistical analysis:
Data will be validated, cleaned and entered in spreadsheet. SPSS program will be used for analysis.
Qualitative data will be presented in frequency and related percentage. Quantitative data with normal distribution will be presented in mean and standard deviation or median and interquartile for non-normally distributed data.
Incidence of positive screening test among the total will be calculated with 95% confidence interval.
Comparison between groups will be done using relevant suitable parametric or non-parametric tests. A "P" value of 0.05 is decided to be the level of significance.
Risk ratios will be calculated for estimation of risk with 95% confidence interval.
Cost per one positive detected screening test will be calculated (Total cost / total positive cases). The direct and indirect costs will be calculated by the laboratory department.
Ethical considerations:
The protocol will be submitted for approval by the University Ethical Research Committee.
The objectives and methods of the research will be explained to the participants.
An informed consent will be obtained from subjects willing to participate in the research and the subjects are free to withdraw from research anytime.
Confidentiality of the data will be highly secured. Positive cases will be reported to the Ministry of Health and Population (MOHP). The guidelines of isolation and treatment protocol of MOHP will be followed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samia Girgis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samia Girgis
vice director of ASU Hospitals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Samia Girgis
Role: PRINCIPAL_INVESTIGATOR
Vice Director of ASU Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center
Cairo, Non-US, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU P29 /2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.